Search for a trial

Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus

Study 1:1) To test the hypothesis that Liraglutide improves cardiovascular function in DM2 patients and whether the improvement is associated with redistribution of ectopic fat stores. 2) To test the hypothesis that Liraglutide activates BAT in DM2…

A clinical outcomes study to evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) in comparison with etanercept (ETA) on the rate of cardiovascular events in patients with moderate to severe rheumatoid arthritis (RA).

Primary ObjectiveThe primary objective of this study is to compare prospectively in patients treated with TCZ or etanercept (ETA), the time to first occurrence of any component of a composite of major adverse cardiovascular events (MACE) consisting…

Comparison of the ABSORB TM Everolimus Eluting Bioresorbable Vascular Scaffold System With a Drug- Eluting Metal Stent (XienceTM) in Acute ST-Elevation Myocardial Infarction

The primary objective of this study is to assess the neointimal healing score (as evaluated by intra-coronary OFDI) in patients with STEMI and treated with Abbott Vascular ABSORB everolimus eluting bioresorbable vascular scaffold (BVS) at 6 months…

Cardiovascular outcomes study to evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ACS) event and type 2 diabetes mellitus (T2D)

To determine whether aleglitazar reduces cardiovasculair mortality and morbidity (defined as non-fatal myocardial infarction (MI) and non-fatal stroke) in patients with a recent ACS event and type 2 diabetes.

A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL
EVALUATING THE SAFETY AND EFFICACY OF EARLY TREATMENT WITH
EPLERENONE IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION

To assess the impact of eplerenone on cardiovascularmortality and morbidity in patients with acutemyocardial infarction (STEMI) when initiated withinthe first 24 hours of onset of symptoms (preferablyduring the first 12 hours)To investigate the…

Effects of low-dose aspirin taken at bedtime vs. on awakening on circadian rhythm of platelet function in healthy subjects

To study the effect of 80 mg aspirin intake at bedtime compared with 80 mg aspirin intake on awakening on circadian rhythm of platelet function in healthy subjects.

Immunoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial parvovirus B19 persistence - a prospective, double-blind, randomized, placebo-controlled clinical trial

A controlled trial to investigate whether high dose of intravenous immunoglobulin (IVIg) in addition to conventional heart failure therapy in patients with idiopathic cardiomyopathy and PVB19 persistence in the heart achieves improvement of cardiac…

Acute and chronic administration of the folate derivate levofolinate to patients with acute myocardial infarction: A double-blinded placebo-controlled pilot study.
"Folate in Acute Myocardial Infarction (FolAMI-study)"

A controlled trial to investigate whether by reducing eNOS uncoupling, by direct super oxide scavenging and by up regulating the high-energy phosphate pool, a high dose of intravenous levofolinate can reduce ischemia- and reperfusion-induced…

A clinical trial comparing treatment with cangrelor (in combination with usual care) to usual care, in subjects who require percutaneous coronary intervention

The primary objective of this study is to demonstrate that the efficacy of cangrelor (combined with usual care) is superior to that of usual care, in subjects requiring percutaneous coronary intervention (PCI) as measured by a composite of all-cause…

The effect of two different heart-lung machines, Twin-Pulse Life Support and standard used heart-lung machine, on the systemic inflammation and pattern of microvascular blood flow. A prospective randomised clinical trial.

Analysis of the effects of the Twin-Pulse Life Support on on the systemic inflammatory response and the effect on microvascular blood flow in ocmparison to standard used Extracorporeal Circuit Device

Extension 1 to Protocol
A 2 year extension to a 36-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren on the prevention of left ventricular remodeling in high risk post-acute myocardial infarction patients when added to optimized standard therapy

The primary objective of this 2 year extension study (CSPP100A2340E1) is to provide additional long-term safety data in this patient population as a post marketing commitment to the EMEA. A secondary objective is to provide additional follow-up data…

A 36 week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren on the prevention of left ventricular remodeling in high risk post-acute myocardial infarct patients when added to optimized standard therapy

The primary objective of this trial is to demonstrate that aliskiren 300 mg, in addition to standard therapy, has superior efficacy compared to placebo in reducing the primary index of adverse cardiac remodeling (defined as the change in LVESV from…

A multicentre, international, phase 3, double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of daily oral dosing of tafamidis meglumine (PF-06291826) 20 mg or 80 mg in comparison to placebo in subjects diagnosed with transthyretin cardiomyopathy (TTR-CM).

The objective of this study is to determine the efficacy, safety, and tolerability of tafamidis in subjects with transthyretin cardiomyopathy.The primary objective is to assess the efficacy, safety, and tolerability of an oral dose of 20 mg or 80 mg…

PHOspholamban RElated CArdiomyopathy STudy - intervention (i-PHORECAST)

The primary objective is to show that eplerenone treatment reduces progression of disease in presymptomatic PLN R14del-carriers

Randomized Evaluation of short-term DUal anti platelet therapy in patients with acute coronary syndrome treated with the COMBO dual-therapy stEnt

To evaluate safety of 3-months versus standard 12-months of DAPT

Bivalirudin Infusion for Ventricular Infarction Limitation

The study hypothesis is that anticoagulation with bivalirudin for primary PCI in STEMI subjects with a 4 h infusion post-PCI will reduce infarct size compared with anticoagulation with UFH as assessed by CMR 5 days after the index event.The primary…

The effect of intracoronary reinfusion of bone marrow-derived mononuclear cells (BMMNC) on all causemortality in acute myocardial infarction

To demonstrate that a single intracoronary infusion of autologous bone marrow-derived mononuclear cells in addition to state of the art treatment is safe and reduces allcause mortality in patients with reduced left ventricular ejection fraction (…

A multi-center, randomized, double-blind, active-controlled, parallelgroup Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk
patients following an acute myocardial infarction

The purpose of this study is to evaluate the efficacy and safety of LCZ696 compared to ramipril, in reducing the occurrence of cardiovascular (CV) death, heart failure (HF) hospitalization and outpatient HF (time-to-first event analysis) in post-AMI…

IOCYTE AMI-3: A Phase 3, Randomized, Double-Blind, Placebo- Controlled, Multicenter Study of Intravenous FDY-5301 in Patients with an Anterior ST-Elevation Myocardial Infarction

This study has been transitioned to CTIS with ID 2024-514372-40-00 check the CTIS register for the current data. Primary objective: To assess the effect of FDY-5301 on cardiovascular mortality and heart failure events in subjects with an anterior…

Multi-center, double-blind, randomized, placebo-controlled, parallel-group
study to evaluate the efficacy and safety of self-administered
subcutaneous selatogrel for prevention of all-cause death and treatment of
acute myocardial infarction in subjects with a recent history of acute
myocardial infarction

This study has been transitioned to CTIS with ID 2023-505438-85-00 check the CTIS register for the current data. The primary objective of the study is to assess the clinical efficacy of selatogrel when self-administered upon occurrence of…